C. Daniel Mullins

 

Latest News:

Professor Mullins was recently interviewed on the economics of personalized medicine for the Winter 2014 edition of the Personalized Medicine Coalition (PMC)’s newsletter.

The PATIENTS Program received a five-year, $5 million grant from the Agency for Healthcare Research & Quality (AHRQ)!  

Professor Mullins awarded the University System of Maryland’s Wilson H. Elkins Professorship!

Welcome to our newest Postdoctoral Fellow, Daisuke Goto, PhD who joins our team after completing his PhD in Economics at Rutgers University!

 
 

C. Daniel Mullins, PhD is a professor in the Pharmaceutical Health Services Research Department (PHSR) at University of Maryland School of Pharmacy.

Prof. Mullins’ research and teaching focus on pharmacoeconomics, comparative effectiveness research, patient-centered outcomes research, and health disparities research. He has received funding as a Principal Investigator from the Agency for Healthcare Research and Quality (AHRQ), National Institude on Aging (NIA), the National Heart, Lung, and Blood Institute (NHLBI), the Patient-Centered Outcomes Research Institute (PCORI), various pharmaceutical manufacturers including Bayer, Pfizer and Sanofi-Aventis, patent advocacy organizations, and the insurance industry. For more information on Prof. Mullins’ research projects, please see the Research Projects section.

In addition to his faculty appointment, Prof. Mullins also serves as the Associate Director of the Center on Drugs and Public Policy at the School of Pharmacy, as well as the Co-Editor-in-Chief for Value in Health.

Outside the university Prof. Mullins actively conducts training programs, which include continuing education lectures and similar activities for the FDA, professional organizations, and training in developing countries.

Prof. Mullins received his BS in Economics from M.I.T. and his PhD in Economics from Duke University.

VIDEO: Prof. Mullins’ interview from the recent National Pharmaceutical Council (NPC) conference, “Putting Patients First®: Paving a Path to Useful CER.”